Amgen (AMGN) CEO nets new shares after large option exercise

Rhea-AI Filing Summary

Amgen Inc. Chairman, CEO and President Robert A. Bradway reported several equity transactions in the company’s stock. He exercised stock options, receiving 119,782 shares of common stock at $156.35 per share through a derivative exercise.

To cover the option exercise price and related tax withholding, 84,285 shares of common stock were withheld by the company and disposed of under a tax-withholding arrangement. After these transactions, Bradway directly owned 492,643 shares of Amgen common stock, and also had indirect ownership of 90,000 shares held through a GRAT and a spousal GRAT.

The directly owned shares include 2,414 dividend equivalents tied to unvested restricted stock units, which will be paid in Amgen common stock on a one-to-one basis as those units vest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bradway Robert A

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320-1799

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		119,782(1)	A	$156.35	576,928	D
Common Stock	03/04/2026		F		84,285	D	$379.27	492,643(2)	D
Common Stock								90,000	I	By GRAT
Common Stock								90,000	I	By Spousal GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	$156.35	03/04/2026		M			119,782	05/03/2018	05/03/2026	Common Stock	119,782	$0	0	D

Explanation of Responses:

1. Non-market exercise of a total of 119,872 stock options expiring May 3, 2026 wherein 84,285 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.

2. These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Robert A. Bradway	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Amgen (AMGN) CEO Robert Bradway report?

Robert A. Bradway reported exercising stock options into 119,782 Amgen common shares and a related tax-withholding share disposition. He also updated his direct and indirect share holdings, reflecting both the option exercise and shares held through GRAT and spousal GRAT structures.

How many Amgen (AMGN) shares does the CEO directly own after this Form 4?

After these transactions, Robert A. Bradway directly owns 492,643 shares of Amgen common stock. This total includes dividend equivalents tied to unvested restricted stock units that will convert into shares as they vest according to Amgen’s equity incentive plan.

What was the price for the Amgen (AMGN) shares acquired through option exercise?

The common shares acquired via option exercise were issued at $156.35 per share. This exercise converted non-qualified stock options into 119,782 shares of Amgen common stock as part of Bradway’s equity compensation, according to the reported derivative exercise transaction.

Why were 84,285 Amgen (AMGN) shares disposed of in the CEO’s Form 4?

A total of 84,285 Amgen shares were withheld and disposed of to cover the stock option exercise price and associated tax withholding. This was a non-market, tax-withholding disposition, meaning shares were used to satisfy obligations rather than sold in open market transactions.

What indirect Amgen (AMGN) holdings does the CEO report?

Bradway reports indirect ownership of 90,000 Amgen common shares, split between a GRAT and a spousal GRAT. These grantor retained annuity trusts hold the shares for estate and wealth-planning purposes, and are shown separately from his directly owned Amgen share holdings.

What are the dividend equivalents mentioned in the Amgen (AMGN) Form 4?

The filing notes 2,414 dividend equivalents credited under Amgen’s equity incentive plan. These dividend equivalents are linked to unvested restricted stock units and will be paid out in Amgen common stock on a one-to-one basis as the underlying restricted stock units vest over time.